• OPEN AN ACCOUNT
Indian Indices
Sensex
83,919.71 897.96
( 1.08%)
Global Indices
Nasdaq
48,502.41 -615.65
(-1.25%)
Dow Jones
6,987.82 -209.01
(-2.90%)
Hang Seng
56,657.02 -2,787.19
(-4.69%)
Nikkei 225
10,369.59 -83.09
(-0.79%)
Forex
USD-INR
93.34 -0.08
(-0.09%)
EUR-INR
102.47 -0.06
(-0.06%)
GBP-INR
122.55 -0.48
(-0.39%)
JPY-INR
0.58 0.00
(-0.32%)

EQUITY - MARKET SCREENER

Industry :  
BSE Code
ISIN Demat
Book Value()
NSE Symbol
P/E(TTM)
Mar.Cap( Cr.)
EPS(TTM)
Face Value()
Div & Yield %
 

Natco Pharma's Visakhapatnam unit concludes USFDA inspection
Nov 20,2026
Natco Pharma announced that the U.S. Food and Drug Administration (FDA) had conducted an inspection at the Finished Dosage Formulations (FDF) manufacturing plant located in Parawada, Visakhapatnam, Andhra Pradesh, India, which was conducted from August 17th – August 21st, 2026. On conclusion of the inspection, the Company had received 4 (Four) observations in the Form-483.

Subsequently, the Company has received Establishment Inspection Report (EIR) from the U.S. FDA on the classification of the above referred inspection as Voluntary Action Indicated (VAI).